New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing